Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Hirata, C. Shimizu, K. Yonemori, A. Hirakawa, T. Kouno, K. Tamura, M. Ando, N. Katsumata, Y. Fujiwara (2009)
Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerBritish Journal of Cancer, 101
T. Shet, A. Agrawal, R. Chinoy, R. Havaldar, V. Parmar, R. Badwe (2007)
Changes in the Tumor Grade and Biological Markers in Locally Advanced Breast Cancer after Chemotherapy – Implications for a PathologistThe Breast Journal, 13
M. Forouzanfar, Kyle Foreman, A. Delossantos, R. Lozano, Alan Lopez, C. Murray, M. Naghavi (2011)
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysisThe Lancet, 378
A. Rhodes, B. Jasani, A. Balaton, D. Barnes, K. Miller (2000)
Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screeningJournal of Clinical Pathology, 53
G. Hortobagyi, J. Salazar, K. Pritchard, D. Amadori, R. Haidinger, C. Hudis, H. Khaled, Mei-Ching Liu, Miguel Martín, M. Namer, J. O’Shaughnessy, Z. Shen, K. Albain (2005)
The global breast cancer burden: variations in epidemiology and survival.Clinical breast cancer, 6 5
A. Ring, I. Smith, S. Ashley, L. Fulford, S. Lakhani (2004)
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerBritish Journal of Cancer, 91
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, Fred Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 16
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
(2001)
National Cancer registry program consolidated report of the population based cancer registries 1990–1996
S. Ven, V. Smit, T. Dekker, J. Nortier, J. Kroep (2010)
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer treatment reviews, 37 6
M. Dowsett, A. Dunbier (2008)
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast CancerClinical Cancer Research, 14
H. Neubauer, C. Gall, U. Vogel, R. Hornung, D. Wallwiener, E. Solomayer, T. Fehm (2008)
Changes in tumour biological markers during primary systemic chemotherapy (PST).Anticancer research, 28 3B
(2008)
Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer
Abstract Neoadjuvant chemotherapy forms the initial modality of treatment for primarily inoperable locally advanced breast cancer (LABC). Breast cancer is characterized by cellular heterogeneity. A change in hormone receptor status after neoadjuvant chemotherapy (NACT) has important therapeutic and prognostic consequences. Data on the influence of neoadjuvant chemotherapy on estrogen receptors (ER) and progesterone receptors (PR) are limited. The primary objective of this study is to compare hormone receptor (HR) status before and after neoadjuvant chemotherapy (discordance) in Indian patients. The secondary objective is to study correlation between tumor response and hormone receptor expression. This is a descriptive study of 78 LABC patients who received neoadjuvant chemotherapy from October 2012 to October 2014. All patients who underwent core biopsy and ER/PR assessment before and after NACT were included in the study. Data was collected prospectively from each patient in a structured proforma. Patients were classified as Group A (ER+, PR+), Group B (ER+, PR-), Group C (ER-, PR+), Group D (ER-, PR-). The HR discordance rate & response to neoadjuvant chemotherapy was assessed. Total HR discordance rate was 21.7 %. The ER discordance was 8.7 % and PR discordance was 13 %. PR positive to PR negative discordance was the predominant one. The pathological complete remission (pCR) rate of endocrine responsive patients was 10.2 % and in the endocrine unresponsive group it was 13.8 %. ER/PR status can change after chemotherapy, hence they need to be re-evaluated after neoadjuvant chemotherapy. This becomes therapeutically important when receptor negative becomes positive.
Indian Journal of Surgical Oncology – Springer Journals
Published: Sep 1, 2016
Keywords: surgical oncology; oncology; surgery
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.